Recs Developed for Neoadjuvant Chemo in Ovarian Cancer

This article originally appeared here.
Share this content:
Recs Developed for Neoadjuvant Chemo in Ovarian Cancer
Recs Developed for Neoadjuvant Chemo in Ovarian Cancer

TUESDAY, Aug. 9, 2016 (HealthDay News) -- Guidelines have been developed for neoadjuvant chemotherapy use for newly diagnosed, advanced ovarian cancer. The clinical practice guideline was published online Aug. 8 in the Journal of Clinical Oncology.

Alexi A. Wright, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues offer guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction in women with stage IIIC or IV epithelial ovarian cancer. The primary evidence base for recommendations was four phase III clinical trials.

The authors note that all women with suspected stage IIIC or IV invasive epithelial ovarian cancer should undergo gynecologic oncologist assessment before initiation of treatment. The primary clinical evaluation should include abdomen and pelvis computed tomography (CT) and chest imaging (ideally CT). Neoadjuvant chemotherapy is recommended for women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to <1 cm of residual disease. Women with potentially resectable disease who are fit for primary cytoreductive surgery may receive neoadjuvant chemotherapy or primary cytoreductive surgery. If there is a high likelihood of achieving cytoreduction to <1 cm with acceptable morbidity, primary cytoreductive surgery is preferred. All patients should have confirmation of an invasive ovarian, fallopian tube, or peritoneal cancer before neoadjuvant chemotherapy is delivered.

"For women with advanced ovarian cancer, decision-making regarding first-line treatment should be a process that is shared between clinicians and their patients," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »